MIRM — Mirum Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $5.61bn
- $5.92bn
- $521.31m
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
Mirum's liver infection drug lowers virus levels in late-stage study (updated)
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake
Mirum's liver infection drug lowers virus levels in late-stage study
U.S. STOCKS ON THE MOVE-WhiteHawk, Mirum Pharmaceuticals, Nvidia
Mirum rises on FDA nod for rare bone disorder drug
US FDA approves Mirum's drug for rare bone disorder (updated)
US FDA approves Mirum's drug for rare bone disorder
Brief: Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule
Mirum Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Mirum Pharmaceuticals Q2 sales rise, lifts outlook
Brief: Mirum Pharmaceuticals Q2 Product Sales USD 176.243 Million
Mirum Pharmaceuticals Inc expected to post a loss of 68 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Nike, Watts Water Technologies
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Brief: Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)